PureTech Health PLC Gelesis & Vedanta Data at Digestive Disease Week
14 Mayo 2019 - 1:01AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
14 May 2019
14 May 2019
PureTech Health plc
PureTech Health Affiliates Gelesis and Vedanta Biosciences
Announce Presentations at Digestive Disease Week
Gelesis presents first clinical data for GS500 prototype for
chronic idiopathic constipation
Vedanta presents expanded Phase 1a/1b study data of lead
candidate, VE303, for recurrent Clostridium difficile infection
BOSTON, May 14, 2019-PureTech Health plc (LSE: PRTC) ("PureTech
Health"), an advanced biopharmaceutical company developing novel
medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis,
today announced that its affiliates Gelesis and Vedanta Biosciences
will deliver poster presentations of clinical data at Digestive
Disease Week, the world's largest gathering of physicians,
researchers, and industry in the fields of gastroenterology,
hepatology, endoscopy, and gastrointestinal surgery.
Gelesis will present clinical data from a study of CSP01 (a
prototype of the investigational hydrogel candidate GS500, in
development for chronic idiopathic constipation (CIC)), which
demonstrated that CSP01 provided a statistically significant
reduction in colonic transit time in patients with CIC relative to
placebo.
Vedanta Biosciences will present expanded, longer-term data from
its successfully completed Phase 1a/1b study of VE303, the
company's lead, orally-administered live biotherapeutic product
candidate for recurrent Clostridium difficile infection.
Details of the presentations are as follows:
Gelesis
Session Date and Time: May 19, 2019 from 12:00 PM to 2:00 PM
Session Title: Constipation and Other Functional Colonic
Syndromes
Presentation Title: CSP01, A Novel Superabsorbent Hydrogel,
Reduces Colonic Transit Time In Chronic Idiopathic Constipation:
Results From A Pilot Randomized, Double-Blind, Placebo-Controlled
Trial
Poster Number: Su1638
Vedanta Biosciences
Session Date and Time: May 20, 2019 from 12:00 PM to 2:00 PM
Presentation Title: VE303, A Live Biotherapeutic Product For
Prevention of Recurrent Clostridioides Difficile (C. Difficile)
Infection. Preliminary Results Of A Phase 1, Open-Label Healthy
Volunteers Study Of Oral VE303 After Vancomycin
Poster Number: Mo1955
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing BIG medicines for dysfunctions of the
Brain-Immune-Gut axis. The Company has gained deep insights into
the connection between these systems and the resulting role in
diseases that have proven resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech Health is developing new categories of medicines with the
potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies with an unbiased, non-binary, and capital efficient
R&D model across its affiliates and its internal labs.
PureTech's affiliates include seven clinical-stage platforms,
including one product that has been cleared by the US Food and Drug
Administration (FDA) and a second product candidate that has been
filed with the FDA for review, and several other novel preclinical
programmes. The PureTech Health pipeline includes ground-breaking
platforms and therapeutic candidates that were developed in
collaboration with some of the world's leading experts.
PureTech's internal research and development is centred on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive
mechanisms in oncology and novel approaches that harness the
lymphatic infrastructure.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAZMGMKMFFGLZZ
(END) Dow Jones Newswires
May 14, 2019 02:01 ET (06:01 GMT)
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024